Study of the safety and immune response of an investigational mRNA vaccine for the prevention of respiratory syncytial virus and/or human metapneumovirus in participants aged 18 to 49 years and 60 years and older

Trial Identifier: VAV00027
Sponsor: Sanofi Pasteur, a Sanofi Company
Start Date: January 2024
Primary Completion Date: February 2025
Study Completion Date: February 2025
Condition: Metapneumovirus immunisation; Respiratory Syncytial Virus Immunisation; Healthy Volunteers

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Australia Canberra, Australia, 2617
Australia, New South Wales Blacktown, New South Wales, Australia, 2148
Australia, New South Wales Kanwal, New South Wales, Australia, 2259
Australia, Queensland Herston, Queensland, Australia, 4006
Australia, Queensland Morayfield, Queensland, Australia, 4506
Australia, Victoria Camberwell, Victoria, Australia, 3124
AUSTRALIA, New South Wales Botany, New South Wales, AUSTRALIA, 2019
AUSTRALIA, New South Wales Sydney, New South Wales, AUSTRALIA, 2035
United States, Florida Hallandale Beach, Florida, United States, 33009
United States, Idaho Meridian, Idaho, United States, 83642
United States, New York Binghamton, New York, United States, 13905
United States, Ohio Cleveland, Ohio, United States, 44122
United States, South Carolina North Charleston, South Carolina, United States, 29405
United States, Virginia Charlottesville, Virginia, United States, 22911
UNITED STATES, California Gardena, California, UNITED STATES, 90247
UNITED STATES, Iowa Sioux City, Iowa, UNITED STATES, 51106
UNITED STATES, Louisiana New Orleans, Louisiana, UNITED STATES, 70119